Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

OvariAn Secretome and Integrated HealthSpan (OASIS)

19 november 2026 uppdaterad av: Dr. Abigail Goshen, Sheba Medical Center

A Three-Part Study of Ovarian Aging, Circulating Molecular Signatures, and Multidomain Healthspan in Women

The OASIS study aims to identify and characterize circulating molecular signatures associated with ovarian aging, and to determine how these signatures relate to multidomain healthspan during the menopausal transition. The study consists of three parts. Part 1 is a retrospective analysis of existing clinical data and stored biospecimens from approximately 500 women aged 50-85 years. Part 2 is a prospective cohort of 300 women aged 40-50 years who will undergo comprehensive clinical, gynecological, and molecular assessments over 24 months, followed by individualized medical management based on their clinical findings. Part 3 (PRISM) is a nested substudy involving up to 30 women from the prospective cohort who will undergo intensive hormonal and ultrasound monitoring across a single menstrual cycle.

Studieöversikt

Detaljerad beskrivning

Background and Purpose:

The menopausal transition is a biologically dynamic period involving changes in ovarian reserve, endocrine function, and morphology that parallel shifts in body composition, bone, cardiovascular, metabolic, sleep, and cognitive health. Because conventional endocrine markers (estradiol, FSH, LH, AMH) do not provide a complete molecular readout of ovarian biology across this transition, OASIS will establish an integrated biological framework linking ovarian aging with systemic molecular physiology using advanced multi-omics profiling.

Part 1: Retrospective OASIS Biobank Cohort This phase includes approximately 500 women aged 50-85 years who previously participated in research at Sheba Medical Center and signed the applicable Biobank consent. The study utilizes existing coded demographic, clinical, and lifestyle data, alongside stored plasma samples. No new patient contact or procedures are required.

Part 2: Prospective OASIS Cohort

This phase will enroll 300 women aged 40-50 years. Participants will complete three study visits over two years:

Baseline (Month 0) and Month 12: Comprehensive multidomain clinical assessment, standardized gynecological evaluation, transvaginal ultrasound (uterus and ovaries), and biospecimen collection for clinical testing and biospecimen banking.

Month 24: A limited follow-up visit including a medical update, the Menopause Rating Scale (MRS) and selected questionnaires, fasting reproductive-hormone testing (including AMH), biospecimen collection, and a gynecological/ultrasound assessment.

Clinical Management: Following the baseline visit, participants will receive their validated clinical results, a medical summary, and individualized recommendations. Management is tailored to the participant's specific clinical findings and may include lifestyle modifications and consideration of Hormone Replacement Therapy/Menopausal Hormone Therapy (HRT/MHT) when clinically indicated.

Part 3: PRISM Nested Intensive Substudy (Precision Reproductive Imaging and Secretome Monitoring) Participation in PRISM is optional and requires separate informed consent. Up to 30 women from Part 2 may participate in up to four additional visits, separate from the main OASIS baseline visit, during a single menstrual cycle.

Studietyp

Observationell

Inskrivning (Beräknad)

800

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studieorter

    • Tel Aviv
      • Ramat Gan, Tel Aviv, Israel, 5262000
        • Sheba Medical Center
        • Kontakt:
          • Abigail Goshen
          • Telefonnummer: 972542270050
        • Huvudutredare:
          • Abigail Goshen, PhD
        • Huvudutredare:
          • Lauren Petrick, PhD
        • Underutredare:
          • Yaron Rabinovici, Dr

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

40 år till 85 år (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Ja

Kön som är behöriga för studier

Kvinna

Testmetod

Icke-sannolikhetsprov

Studera befolkning

Part 1, retrospective biobank cohort: women aged 50 years and above Parts 2 and 3, prospective main cohort and nested PRISM cohort: women aged 40-50 years

Beskrivning

Inclusion Criteria:

  • Women aged 50-85 years at enrollment (for part 1 retrospective study). or
  • Women aged 40-50 years at enrollment (for part 2 prospective study).
  • Able to understand the study information and provide written informed consent.
  • Able and willing to complete the study assessments and follow-up visits.

Part 3 (PRISM substudy) specific criteria:

  • Natural, regular menstruation.
  • Reported menstrual-cycle length of 21-35 days.
  • Willing and able to attend four additional blood-draw and transvaginal ultrasound visits across one menstrual cycle.
  • Signed separate PRISM informed consent.
  • Not using oral contraceptives, other hormonal contraceptives, menopausal hormone therapy, or another hormonal treatment at PRISM enrollment.

Exclusion Criteria:

  • A former diagnosis of significant cognitive reduction (MoCA score <24).
  • Former diagnosis of a neurodegenerative disease such as Alzheimer's disease, Parkinson's disease, or Lewy body dementia.
  • Former diagnosis of psychiatric disease.
  • Underwent chemotherapy or radiation therapy in the past two years.

Part 3 (PRISM substudy) specific criteria:

  • Failure to meet the PRISM inclusion criteria.
  • Unwillingness or inability to sign the PRISM consent.
  • Irregular cycle or reported cycle length outside 21-35 days.
  • Current hormonal contraceptive, menopausal hormone therapy or other hormonal treatment.
  • Inability or unwillingness to undergo repeated blood draws.
  • Inability or unwillingness to undergo transvaginal ultrasound.
  • A medical condition that, in the investigator's judgment, makes participation unsafe or unsuitable.
  • A medical, technical, or logistical reason that precludes reliable completion of the substudy.
  • Pregnancy, breastfeeding, initiation of hormonal treatment, or a significant medical change during PRISM must be reported to the study team and may lead to discontinuation at the Principal Investigator's discretion.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Observationsmodeller: COHORT
  • Tidsperspektiv: OTHER

Kohorter och interventioner

Grupp / Kohort
Part 1: Retrospective Biobank Cohort

500 women aged 50 years and older with available clinical data and stored biospecimens from the Sheba Biobank. Evaluation is limited to retrospective data extraction and molecular analysis.

Part 2: Prospective Main Cohort

300 women aged 40-50 years undergo longitudinal clinical, multidomain, and gynecological assessments at Baseline, Month 12, and Month 24, and provide biosamples. Participants receive individualized clinical management (including potential HRT/MHT) based on the clinical findings.

Part 3: PRISM Nested Substudy

Up to 30 women co-enrolled from Part 2. Participants undergo intensive repeated measures (transvaginal ultrasound and blood sampling for hormone/molecular analysis) across up to four visits during a single menstrual cycle to assess short-term longitudinal changes.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Reproductive hormone concentrations
Tidsram: Baseline, 12 months, 24 months

The concentrations of anti-Müllerian hormone (AMH), follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol, and progesterone will be measured in blood samples.

Baseline, 12 months, 24 months
Antral Follicle Count (AFC)
Tidsram: Baseline, 12 months, 24 months

The total number of antral follicles in both ovaries will be assessed using transvaginal ultrasound.

Baseline, 12 months, 24 months
Total ovarian volume
Tidsram: Baseline, 12 months, 24 months

Ovarian volume in milliliters will be measured using transvaginal ultrasound. Total ovarian volume will be calculated based on measurements of both ovaries.

Baseline, 12 months, 24 months
Number of participants with abnormal ovarian or adnexal ultrasound findings
Tidsram: Baseline, 12 months, 24 months

The number and proportion of participants with abnormal ovarian morphology, ovarian cysts, or other abnormal adnexal findings identified by transvaginal ultrasound will be recorded.

Baseline, 12 months, 24 months
Circulating ovarian-associated molecular signature
Tidsram: Baseline, 12 months

Plasma protein levels will be assessed using high-throughput proteomic profiling with the Olink Explore HT platform to characterize circulating molecular signatures associated with ovarian function.

Baseline, 12 months
Montreal Cognitive Assessment (MoCA) score
Tidsram: Baseline, 12 months

Cognitive function will be assessed using the Montreal Cognitive Assessment (MoCA). The total score ranges from 0 to 30, with higher scores indicating better cognitive performance.

Baseline, 12 months
Apnea-Hypopnea Index (AHI)
Tidsram: Baseline, 12 months

Sleep apnea severity will be assessed by measuring the Apnea-Hypopnea Index (AHI), defined as the number of apnea and hypopnea events per hour of sleep.

Baseline, 12 months
Glycated hemoglobin (HbA1c)
Tidsram: Baseline, 12 months

Glycemic control will be assessed by measuring the percentage of glycated hemoglobin (HbA1c) in blood samples.

Baseline, 12 months
DXA-derived body composition
Tidsram: Baseline, 12 months

Body composition will be assessed using dual-energy X-ray absorptiometry (DXA), including measurements of fat mass and lean mass (kg).

Baseline, 12 months
Bone mineral density (BMD)
Tidsram: Baseline, 12 months

Bone mineral density (BMD) will be measured using dual-energy X-ray absorptiometry (DXA) at the lumbar spine, femoral neck, and total hip. Results will be reported in g/cm².

Baseline, 12 months
Handgrip strength
Tidsram: Baseline, 12 months

Physical function will be assessed by measuring handgrip strength using a calibrated hand dynamometer. Results will be reported in kilograms (kg).

Baseline, 12 months
Pulse wave velocity (PWV)
Tidsram: Baseline, 12 months

Arterial stiffness will be assessed by measuring pulse wave velocity (PWV). Results will be reported in meters per second (m/s).

Baseline, 12 months
Within-woman changes in reproductive endocrine measures
Tidsram: Up to four sampling time points during the first month of the study

Serial measurements of AMH, FSH, LH, estradiol, and progesterone concentrations in blood samples will be performed to assess short-term hormonal fluctuations within participants.

Up to four sampling time points during the first month of the study

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Samarbetspartners

Utredare

  • Huvudutredare: Abigail Goshen, PhD, Sheba Medical Center

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Beräknad)

2 november 2026

Primärt slutförande (Beräknad)

1 november 2029

Avslutad studie (Beräknad)

1 maj 2030

Studieregistreringsdatum

Först inskickad

22 oktober 2026

Först inskickad som uppfyllde QC-kriterierna

19 november 2026

Första postat (Faktisk)

20 november 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

20 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

19 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Andra studie-ID-nummer

  • 3577-26-SMC
  • OD-2026001 (Annat bidrag/finansieringsnummer: Nuttall Women's Health (NWH))

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

OBESLUTSAM

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera